- New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
- Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
- Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
- Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
- Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
- New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
- Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
- Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
- Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
More ▼
Key statistics
On Wednesday, Myriad Genetics Inc (MYGN:NSQ) closed at 23.99, -7.55% below its 52-week high of 25.95, set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.27 |
---|---|
High | 24.93 |
Low | 23.88 |
Bid | 23.50 |
Offer | 25.24 |
Previous close | 24.38 |
Average volume | 952.34k |
---|---|
Shares outstanding | 90.51m |
Free float | 88.62m |
P/E (TTM) | -- |
Market cap | 2.21bn USD |
EPS (TTM) | -2.82 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼